Molina Healthcare, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MOH research report →
Range $163 – $286
Price Chart
About the company
Molina Healthcare, Inc. offers comprehensive managed health care services, primarily targeting economically disadvantaged families and individuals. The company provides coverage through key government initiatives such as Medicaid and Medicare programs, in addition to state health insurance marketplaces.
- CEO
- Joseph Michael Zubretsky
- IPO
- 2003
- Employees
- 19,000
- HQ
- Long Beach, CA, US
AI snapshot
Six angles, distilled from the data.
MOH is still in a longer-term recovery regime, holding above its 200-day average of 186.26 and well off the 52-week low of 121.06. The stock remains below its 52-week high of 244.89, so the setup is constructive but not fully repaired after a volatile year.
Street sentiment is cautious-to-positive: the consensus sits at Buy with a 217.42 target, above the current share price but not by a wide margin. Recent action has been mostly target raises and repeated hold calls, which points to improving expectations without a full rerating.
The earnings backdrop is mixed but improving. MOH has beaten EPS in 4 of the last 8 quarters, including a 23.6% beat last quarter, and next-year EPS estimates are still pointed sharply higher to 9.5378 from a negative TTM EPS of -0.68. Shareholders should watch whether margin repair continues after a weak revenue and earnings year.
Recent insider activity leans negative on discretionary trades, with 4 sells and no buys. The sales from a director and the chief legal officer outweigh routine award and gift-related entries, so the signal is cautious rather than supportive.
Profitability is thin but not broken: gross margin is 8.4%, operating margin is 0.64%, and net margin is -0.11%. Revenue fell 3.5% year over year and earnings fell 51.5%, but the balance sheet is strong with $8.256 billion in cash versus $3.95 billion of debt and $4.306 billion in net cash.
MOH trades as a managed-care name with a premium profile versus many healthcare plans, supported by a 29.38 P/E and a market cap above $10 billion. The valuation still assumes a recovery, so execution matters more than sector multiple expansion.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.36B
- P/E
- -338.62
- Fwd P/E
- 37.74
- PEG
- 3.26
- P/S
- 0.25
- P/B
- 2.56
- EV/EBITDA
- 30.79
- Div Yield
- 0.00%
- Gross Margin
- 8.06%
- Op Margin
- 0.39%
- Net Margin
- -0.11%
- ROE
- -1.17%
- ROIC
- 2.08%
Latest fiscal year · YoY change
- Revenue
- $45.43B+11.7%
- Gross Profit
- $4.08B-14.0%
- Op Income
- $781.00M
- Net Income
- $472.00M-60.0%
- EPS
- $8.93-56.5%
- OCF Growth
- -183.1%
- FCF Growth
- -216.9%
- 52W High
- $244.89
- 52W Low
- $121.06
- 50D MA
- $204.03
- 200D MA
- $186.51
- Beta
- 0.74
- RSI (14)
- 44
- Avg Volume
- 798.09K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Molina delivered a solid Q3 with earnings and margins in line with expectations, reaffirmed 2026 guidance, and laid out a constructive early view for 2027 despite a delayed Georgia/Texas contract ramp and ongoing Medicaid pressure.· October 22, 2026
- Q3 adjusted EPS was $0.89 on about $10.5 billion of premium revenue, with consolidated MCR at 92.9% and adjusted pre-tax margin at 0.6%.
- 2026 guidance was reaffirmed: premium revenue of approximately $42 billion and adjusted EPS of at least $5.25, with full-year consolidated MCR at 92.6% and G&A at 6.4%.
- Management raised the full-year 2026 rate outlook to 4.5% and trend outlook to 5.5%, citing higher utilization and a slight acuity shift.
- Preliminary 2027 premium revenue is expected to be at least $45 billion, but Georgia and Texas contract starts were delayed, pushing out $1.3 billion of premium.
- The company said early 2027 EPS building blocks exceed $9.50 per share, and it still expects legacy Medicaid margins to be at least flat year over year at this stage.
Molina reported adjusted EPS of $0.89 on approximately $10.5 billion of premium revenue in Q3 2026. Consolidated MCR was 92.9%, adjusted G&A ratio was 6.3%, and adjusted pre-tax margin was 0.6%. By segment, Medicaid MCR was 93%, Medicare MCR was 93%, and Marketplace MCR was 92.5%. For full-year 2026, management reaffirmed premium revenue of approximately $42 billion, adjusted EPS of at least $5.25, consolidated MCR of 92.6%, and adjusted G&A of 6.4%. The company now expects 2026 rates of 4.5% and trend of 5.5%, and it said 2027 premium revenue should be at least $45 billion, with preliminary EPS building blocks of more than $9.50 per share.
Joe Zubretsky emphasized that the quarter was solid in a difficult medical cost environment and said Medicaid, Medicare, and Marketplace all came in line with expectations. He highlighted that rate updates are improving, that the rate-trend imbalance in Medicaid appears to be stabilizing, and that current Medicaid margins may represent the trough of a multi-year cycle. His tone on 2027 was optimistic, pointing to strong early rate indications, a likely supportive trend/rate backdrop, a strong Florida CMS launch, and a robust RFP pipeline.
Mark Keim focused on the mechanics behind the numbers and the balance sheet. He said the company ended the quarter with about $600 million of parent cash, harvested $185 million of subsidiary dividends, generated $629 million of operating cash flow in the first nine months of 2026, and had net debt-to-capital of 45%; days in claims payable were 44. He also walked through 2026 guidance, noting that the fourth quarter implies $0.50 of adjusted EPS, the Florida CMS contract is expected to create about a $1 drag in Q4, and the updated rate and trend assumptions are now 4.5% and 5.5%.
Analysts focused on the interplay between better Medicaid rates and expected enrollment losses from work requirements and reverifications, and management said the current read from Nebraska and other states looks more gradual and less severe than feared, with many states leaning toward policies that promote enrollment rather than disenrollment. Questions also centered on Florida CMS, where management said the launch has been nearly flawless and that the contract should move from a roughly 5% pre-tax loss in Q4 to breakeven or better next year. Additional questions addressed the pace of acuity shift, Florida G&A, California eligibility changes, and rate-setting practices; management repeatedly said those effects are already embedded in current outlooks and that several January 1 rate updates explicitly include assumptions for work requirements and redeterminations.
The call presented a credible path to stronger earnings in 2027, supported by higher known rates, a large premium base, and management’s view that Medicaid trend may be plateauing. Management also sounded confident on Florida CMS, the duals strategy, and a sizable RFP pipeline, while saying the existing 2027 building blocks already exceed $9.50 per share before any Medicaid margin improvement.
The main risks are delayed contract timing in Georgia and Texas, which pushed out $1.3 billion of premium, and the still-elevated medical cost environment, especially in Medicaid. Management also expects 2026 and 2027 to be affected by work requirements, reverifications, and acuity shifts, while Marketplace remains under pressure and MAPD is being exited at a loss before discontinuation.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.8%
- Shares Outstanding
- 52.20M
- Float Shares
- 47.90M
of shares held by institutions
637 13F filers
Buy/sell ratio 1.80. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MOH, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Jan 29, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Nov 12, 25 | Filing → |
| Byron DonaldsHouse · FL19 | Sell | Sep 4, 25 | Filing → |
| Byron DonaldsHouse · FL19 | Sell | Sep 4, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Aug 5, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | May 15, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | May 30, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Apr 29, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Sell | Jan 13, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 9, 24 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jul 12, 23 | Filing → |
| Earl BlumenauerHouse · OR03 | Buy | Jun 15, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 23, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 6.08M | ▼ 353.21K |
| Blackrock, Inc. | 5.46M | ▼ 1.11M |
| Aqr Capital Management LLC | 3.56M | ▲ 697.21K |
| Lingotto Investment Management Llp | 3.02M | ▲ 509.66K |
| Capital World Investors | 2.88M | ▲ 314.99K |
| Vanguard Capital Management LLC | 2.35M | ▼ 5.65K |
| Vanguard Portfolio Management LLC | 2.31M | ▼ 476.88K |
| State Street Corp | 1.70M | ▼ 54.57K |
| Fmr LLC | 1.41M | ▼ 457.86K |
| Dimensional Fund Advisors LP | 1.32M | ▼ 68.91K |
| Goldman Sachs Group Inc | 1.31M | ▲ 579.68K |
| Wellington Management Group Llp | 1.27M | ▲ 135.25K |
Held by 708 ETFs
Biggest fund positions in MOH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | ORLANDO STEVEN J | sell | 702 |
| Nov 13, 26 | WOLF DALE B | sell | 1,600 |
| Nov 13, 26 | Zubretsky Joseph M | other | 6,500 |
| Mar 1, 24 | Zubretsky Joseph M | other | 16,735 |
| Mar 1, 24 | Zubretsky Joseph M | other | 10,639 |
| Nov 10, 26 | Schapiro Richard M | sell | 782 |
| Nov 10, 26 | Barlow Jeff D. | sell | 8,000 |
| Oct 1, 26 | ZORETIC RICHARD C | other | 304 |
| Oct 1, 26 | WOLF DALE B | other | 304 |
| Oct 1, 26 | Schapiro Richard M | other | 304 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MOH coverage
Recent articles, reports, and earnings notes.

Molina Healthcare (MOH): Medicaid Reset Sets Up 2027 Recovery
Molina Healthcare faces a sharp 2026 earnings reset, but Medicaid rate normalization and improving Medicare duals could support a 2027 rebound. The stock looks more like a Hold than a Buy while execution risk remains high.

Molina Healthcare (MOH): Recovery Story With Execution Risk
Molina Healthcare is a large government-sponsored managed care franchise with a strong balance sheet and a clear growth pipeline, but recent earnings have been pressured by medical cost inflation and contract churn. The report rates MOH a Buy, with upside tied to a recovery in margins and execution on Medicaid, Medicare, and Florida.

Molina Healthcare, Inc. (MOH) falls 10% on after-hours selloff
Molina Healthcare, Inc. (MOH) falls sharply after hours after an S&P MidCap 400 rebalance and renewed managed-care margin worries hit the stock. The move came without a fresh earnings report, suggesting trading flows and sector pressure drove the drop more than a new company-specific setback.
Want a deeper read on MOH?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Molina (MOH) Down 6.1% Since Last Earnings Report: Can It Rebound?
zacks.com · Nov 20
Molina Healthcare of Illinois Commits $2.4 Million to Expand Access to Care Across the State
businesswire.com · Nov 18
5 HMO Stocks to Watch Amid Sound Membership Base, Tech Innovation
zacks.com · Nov 17
Molina Healthcare, Inc. (MOH) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 9
Molina Healthcare Q3 Earnings Call Highlights
marketbeat.com · Oct 22
Molina Healthcare, Inc. (MOH) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 22
Molina (MOH) Surpasses Q3 Earnings and Revenue Estimates
zacks.com · Oct 21
Molina (MOH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Oct 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice